16α,17-((Ξ)-ethylLiDenedioxy)-9-fluoro-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione | 3869-38-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子
• 英文名称: 16α,17-((Ξ)-ethylLiDenedioxy)-9-fluoro-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione
• 英文别名: 16α,17-((Ξ)-Aethylidendioxy)-9-fluor-11β,21-dihydroxy-pregna-1,4-dien-3,20-dion；(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,9,13-trimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
• CAS: 3869-38-3
• 化学式: C₂₃H₂₉FO₆
• 分子量: 420.478
• InChiKey: YFZMGMBERXZRPY-OQYZQWETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  曲安西龙 在 高氯酸 、 三聚乙醛 作用下， 生成 16α,17-((Ξ)-ethylLiDenedioxy)-9-fluoro-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione
  参考文献：
  名称：

  CYCLIC 16α,17α-KETALS AND ACETALS OF 9α-FLUORO-16α-HYDROXY-CORTISOL AND -PREDNISOLONE

  摘要：

  DOI：

  10.1021/ja01542a083

文献信息

• PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY
  申请人：Cannizzaro Carina

  公开号：US20090227543A1

  公开（公告）日：2009-09-10

  The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷酸酯取代化合物，具有免疫调节活性，含有这种化合物的组合物，以及包括这种化合物的给药的治疗方法，还涉及用于制备这种化合物的有用过程和中间体。
• ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS
  申请人：Cannizzaro Carina

  公开号：US20090247488A1

  公开（公告）日：2009-10-01

  The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗炎化合物、含有这种化合物的组合物、包括给药这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• CHEMICALLY MODIFIED SMALL MOLECULES
  申请人：Fishburn C. Simone

  公开号：US20120088745A1

  公开（公告）日：2012-04-12

  Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
• US3984544A
  申请人：——

  公开号：US3984544A

  公开（公告）日：1976-10-05
• US7432261B2
  申请人：——

  公开号：US7432261B2

  公开（公告）日：2008-10-07